These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 23908493)
1. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). Fogel JM; Wang L; Parsons TL; Ou SS; Piwowar-Manning E; Chen Y; Mudhune VO; Hosseinipour MC; Kumwenda J; Hakim JG; Chariyalertsak S; Panchia R; Sanne I; Kumarasamy N; Grinsztejn B; Makhema J; Pilotto J; Santos BR; Mayer KH; McCauley M; Gamble T; Bumpus NN; Hendrix CW; Cohen MS; Eshleman SH J Infect Dis; 2013 Nov; 208(10):1624-8. PubMed ID: 23908493 [TBL] [Abstract][Full Text] [Related]
2. Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. Zhang Y; Sivay MV; Hudelson SE; Clarke W; Breaud A; Wang J; Piwowar-Manning E; Agyei Y; Fogel JM; Hamilton EL; Selin A; MacPhail C; Kahn K; Gómez-Olivé FX; Hughes JP; Pettifor A; Eshleman SH J Acquir Immune Defic Syndr; 2018 Nov; 79(3):315-322. PubMed ID: 29985265 [TBL] [Abstract][Full Text] [Related]
3. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo. Dagnra AY; Vidal N; Mensah A; Patassi A; Aho K; Salou M; Monleau M; Prince-David M; Singo A; Pitche P; Delaporte E; Peeters M J Int AIDS Soc; 2011 Jun; 14():30. PubMed ID: 21663632 [TBL] [Abstract][Full Text] [Related]
4. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India. Gupta A; Saple DG; Nadkarni G; Shah B; Vaidya S; Hingankar N; Chaturbhuj D; Deshmukh P; Walshe L; Hudelson SE; James M; Paranjape RS; Eshleman SH; Tripathy S AIDS Res Hum Retroviruses; 2010 Jan; 26(1):25-31. PubMed ID: 20063995 [TBL] [Abstract][Full Text] [Related]
5. HIV drug resistance in persons who inject drugs enrolled in an HIV prevention trial in Indonesia, Ukraine, and Vietnam: HPTN 074. Palumbo PJ; Zhang Y; Fogel JM; Guo X; Clarke W; Breaud A; Richardson P; Piwowar-Manning E; Hart S; Hamilton EL; Hoa NTK; Liulchuk M; Anandari L; Ha TV; Dumchev K; Djoerban Z; Hoffman I; Hanscom B; Miller WC; Eshleman SH PLoS One; 2019; 14(10):e0223829. PubMed ID: 31600343 [TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609 [TBL] [Abstract][Full Text] [Related]
7. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya. Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS). Palella FJ; Armon C; Buchacz K; Chmiel JS; Novak RM; D'Aquila RT; Brooks JT; J Antimicrob Chemother; 2014 Oct; 69(10):2826-34. PubMed ID: 24942257 [TBL] [Abstract][Full Text] [Related]
9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
10. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)]. Panel de expertos de Gesida y Plan Nacional sobre el Sida Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764 [TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of HIV seroconverters in microbicide trials - rationale, study design, and challenges in MTN-015. Riddler SA; Husnik M; Gorbach PM; Levy L; Parikh U; Livant E; Pather A; Makanani B; Muhlanga F; Kasaro M; Martinson F; Elharrar V; Balkus JE; HIV Clin Trials; 2016 Sep; 17(5):204-11. PubMed ID: 27465646 [TBL] [Abstract][Full Text] [Related]
12. Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061. Chen I; Connor MB; Clarke W; Marzinke MA; Cummings V; Breaud A; Fogel JM; Laeyendecker O; Fields SD; Donnell D; Griffith S; Scott HM; Shoptaw S; del Rio C; Magnus M; Mannheimer S; Wheeler DP; Mayer KH; Koblin BA; Eshleman SH J Acquir Immune Defic Syndr; 2015 Aug; 69(4):446-52. PubMed ID: 25861015 [TBL] [Abstract][Full Text] [Related]
13. Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. Tuboi SH; Brinkhof MW; Egger M; Stone RA; Braitstein P; Nash D; Sprinz E; Dabis F; Harrison LH; Schechter M J Acquir Immune Defic Syndr; 2007 May; 45(1):52-9. PubMed ID: 17460471 [TBL] [Abstract][Full Text] [Related]
14. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy. Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D; AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228 [TBL] [Abstract][Full Text] [Related]
15. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure. Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315 [No Abstract] [Full Text] [Related]
16. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study. Mulu A; Maier M; Liebert UG PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902 [TBL] [Abstract][Full Text] [Related]
17. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. Adjé-Touré C; Hanson DL; Talla-Nzussouo N; Borget MY; Kouadio LY; Tossou O; Fassinou P; Bissagnene E; Kadio A; Nolan ML; Nkengasong JN AIDS Res Hum Retroviruses; 2008 Jul; 24(7):911-7. PubMed ID: 18593341 [TBL] [Abstract][Full Text] [Related]
18. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650 [TBL] [Abstract][Full Text] [Related]
19. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation. Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192 [TBL] [Abstract][Full Text] [Related]
20. Impact of Different Antiretroviral Strategies on Total HIV-DNA Level in Virologically Suppressed HIV-1 Infected Patients. Bon I; Calza L; Musumeci G; Longo S; Bertoldi A; D'Urbano V; Gibellini D; Magistrelli E; Viale PL; Re MC Curr HIV Res; 2017; 15(6):448-455. PubMed ID: 29210661 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]